[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592610":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":25,"locations":33,"responsibleParty":54,"collaborators":12,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":12,"enrollmentInfo":66,"targetDuration":12,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":36,"whyStopped":12,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Royal Marsden NHS Foundation Trust","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Control","NO_INTERVENTION","Standard palliative-dose radiotherapy, 30Gy in 10 fractions in 3Gy per fraction over 2 weeks",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Experimental \u002F High-dose","EXPERIMENTAL","High-dose radiotherapy, 30Gy in 5 fractions in 6Gy per fraction on alternate days\u002F2-3 fractions a week over 2 weeks",[18],"Procedure: radiotherapy",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"PROCEDURE","radiotherapy","External Beam Radiotherapy - hypofractionated, short radiotherapy regime of 30Gy in 5 fractions (6Gy per fraction) delivered on alternate days over 2 weeks",[14],[26,31],{"name":27,"role":28,"phone":29,"phoneExt":12,"email":30},"Harshani Green","CONTACT","020 7811 8116","VIRTUAL.Trial@rmh.nhs.uk",{"name":32,"role":28,"phone":29,"phoneExt":12,"email":30},"Sijy Pillai",[34],{"facility":35,"status":36,"city":37,"state":12,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"The Royal Marsden NHSFT","RECRUITING","London","SW3 6JJ","United Kingdom","UK",{"type":42,"coordinates":43},"Point",[44,45],-0.12574,51.50853,{"lat":45,"lon":44},[48,49,52],{"name":32,"role":28,"phone":29,"phoneExt":12,"email":30},{"name":50,"role":51,"phone":12,"phoneExt":12,"email":12},"Vincent Khoo","PRINCIPAL_INVESTIGATOR",{"name":27,"role":53,"phone":12,"phoneExt":12,"email":12},"SUB_INVESTIGATOR",{"type":55,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR","100592610","partial-volume-high-dose-irradiation-in-renal-cell-carcinoma-for-intra-tumoural-control-alongside-current-management-100592610",false,"NCT06995664","Partial Volume High-Dose Irradiation in Renal Cell Carcinoma for Intra-TUmoural Control ALongside Current Management","Partial Volume High-Dose Irradiation in Renal Cell Carcinoma for Intra-TUmoural Control ALongside Current Management - a Randomised Feasibility Study","VIRTUAL","Inclusion Criteria:\n\n* Histologically confirmed renal cell carcinoma (RCC) (histological confirmation of metastasis not required) or clinically consistent with RCC as per multidisciplinary team (MDT) diagnosis.\n* Not suitable for surgical resection, metastasectomy or ablative therapy due to tumour or patient factors\n* All extracranial sites which clinically require radiotherapy (as per clinician discretion)\n* Age ≥18 years\n* Karnofsky Performance Status (KPS) ≥50\n* Adequate baseline organ function applicable to site-of irradiation\n* Haemaglobin ≥90g\u002Fdl\n* Platelets ≥50\n* Bilirubin \\\u003C3x ULN\n* INR \\\u003C1.4 or correctable with vitamin K\n* AST or ALT \\\u003C5x normal range\n* Creatinine \\\u003C200umol\u002FL (or established on dialysis). Note patients on dialysis are unable to have dynamic contrast enhanced MRI.\n* The use of concurrent systemic therapy is acceptable\n* Ability of the research subject to understand and the willingness to sign a written informed consent document\n* Able to undergo all mandated staging and follow-up investigations\n* Negative pregnancy test (for women of childbearing potential)\n\nExclusion Criteria:\n\n* Expected prognosis \\\u003C6 months\n* Uncontrolled intracranial metastases\n* Previous radiotherapy, such that the delivery of further radiotherapy is not feasible\n* Unable to have necessary radiotherapy planning, radiotherapy related investigations\u002Ffiducials (if required)\n* Co-morbidities or any psychological, familial, sociological or geographical condition which may preclude ability to undergo\u002Fattend investigations, treatment or follow-up\n* Other active primary cancer\n* Pregnant or lactating\n* Requiring ongoing treatment with a concomitant medication, which is contraindicated alongside radiotherapy (e.g. methotrexate)","ALL","18 Years",{"count":67,"type":68},24,"ESTIMATED","INTERVENTIONAL",[71],"NA","Prospective, randomised, feasibility study of patients with localised or metastatic renal cell carcinoma (RCC) comparing standard palliative dose radiotherapy to a high-dose hypofractionated regime.\n\nPrimary aim\n\n• To demonstrate feasibility of a randomised study comparing high-dose hypofractionated radiotherapy versus standard palliative dose radiotherapy in localised or metastatic renal cell carcinoma The aim is to recruit a minimum of 24 patients; 12 to the control arm and 12 to the high-dose regime.\n\n2 treatment arms, no placebo:\n\n* Control arm - standard palliative-dose radiotherapy, 30Gy in 10 fractions in 3Gy per fraction over 2 weeks\n* High-dose arm - high-dose radiotherapy, 30Gy in 5 fractions in 6Gy per fraction on alternate days\u002F2-3 fractions a week over 2 weeks",[74,75],"Renal Cell Carcinoma","Renal Cell Carcinoma Metastatic",[77,78,22,79],"standard palliative dose radiotherapy","high-dose hypofractionated radiotherapy","unblinded","2025-05-21",{"date":82,"type":83},"2025-05-29","ACTUAL",{"date":85,"type":83},"2023-03-27",{"date":87,"type":68},"2026-05",{"name":5,"class":6},1]